roztwór do infuzji
Sponsors
Pharmacosmos A/S, Medical University Of Lodz, Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie-Panstwowy Instytut Badawczy, Uniwersytet Jagiellonski Collegium Medicum, Medical University Of Gdansk
Conditions
Acute Myeloid LeucaemiaAcute Myeloid LeukemiaAcute ischemic strokeAcute myeloid leukemiaDiffuse large B-cell lymphoma) and aggressive B-cell lymphomas (HGBCLDiffuse large B-cell lymphomas (DLBCLExtensive Stage Small Cell Lung CancerHER2 negative breast cancer
Phase 1
Phase 2
A phase II study of preoperative stereotactic radiation therapy boost combined with short-course immunotherapy (pembrolizumab versus placebo, randomized, double-blind) and standard chemotherapy in patients with newly diagnosed HER2-negative non-metastatic breast cancer with lack of early metabolic response in 18-fluorodeoxyglucoseFDG-PET/CT after 1st chemoterapy cycle
RecruitingCTIS2023-504145-31-00
Start: 2024-06-10Target: 78Updated: 2024-02-21
Assessment of Tolerance and Effectiveness of Total Body Irradiation and Cladribine Before Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Active, not recruitingCTIS2024-517477-24-00
Start: 2022-02-17Target: 40Updated: 2025-04-02
A phase II efficacy and safety study of cell-free circulating tumor DNA-guided commencement of second-line treatment in patients with DLBCL/HGBCL relapse
Not yet recruitingCTIS2024-518275-64-00
Target: 340Updated: 2025-11-24
A multicentre, parallel group, randomised, double blind, placebo-controlled, phase II study evaluating the efficacy and safety of reperfusion thrombolytic therapy with intravenous recombinant tissue plasminogen activator (rtPA) for ischaemic stroke in patients on the non-vitamin K antagonist oral anticoagulant after reversing anticoagulant activity with the specific antidote
RecruitingCTIS2024-518509-17-00
Start: 2022-01-10Target: 300Updated: 2024-12-09
CLASP MS: The study evaluating the efficacy and safety of Polish cladribine in the treatment of patients with secondary progressive multiple sclerosis - a phase 2, randomized, double-blind, placebo-controlled trial.
Not yet recruitingCTIS2024-516992-33-02
Target: 188Updated: 2025-01-30
Comparison of treatment efficacy in the patients with Systemic sclerOsis: dapagliFlozin vs. Tocilizumab – a randomized head to head study
WithdrawnCTIS2025-523714-92-00
Target: 80Updated: 2025-12-15
Phase 3
A Randomized, Double-Blind, Placebo-Controlled Study of Trilaciclib vs Placebo in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan Chemotherapy
RecruitingCTIS2022-502357-34-00
Start: 2023-09-27Target: 250Updated: 2025-12-18
MAGIC AML - Multiarm, Multicenter, RAndomized, Molecularly-GuIded Controlled Trial of Personalized Treatment Strategy - of Acute Myeloid Leukemia
RecruitingCTIS2023-503394-37-00
Start: 2024-10-23Target: 520Updated: 2025-10-15
The effect of noradrenaline infusion versus standard blood pressure management on perioperative HYPotension in NOncaRdiac surgery.
RecruitingCTIS2023-508255-39-00
Start: 2025-06-16Target: 750Updated: 2025-12-17
A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Levosimendan Therapy in low ejection fraction Takotsubo Syndrome (LevoTako Trial)
CompletedCTIS2024-515060-32-00
Start: 2024-11-22End: 2025-12-22Target: 190Updated: 2025-12-14